Retina specialists review recent developments in research for retinal diseasesApril 7th 2022
Developments in imaging, translational research and clinical trials of treatments for retinal diseases dominated discussion at the two-day Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 virtual conference.
Japanese investigators identify gene required for survival of retinal ganglion cellsMarch 27th 2022
A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells—a class of neurons located in the retina that are critical for vision.
PALADIN Study: Improved visual acuity, CST resulting from fluocinolone acetonide intravitreal implantFebruary 26th 2022
Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular oedema.
The retina may reveal risk of Alzheimer disease in middle ageFebruary 19th 2022
Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.
Gene therapies licensed by Kriya Therapeutics target geographic atrophy, other ocular diseasesFebruary 18th 2022
Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
Investigating Stargardt: RNA, gene therapy options for patientsFebruary 12th 2022
Dr Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.
Avacincaptad pegol slows growth of geographic atrophy lesions for patients in clinical trialFebruary 11th 2022
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation and Degeneration 2022 Virtual Edition, Dr Glenn J. Jaffe noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.